Terms: = Lymphoma AND PR, PGR, progesterone receptor AND Treatment
1231 results:
1. Tailoring Radiation Therapy for Patients With Limited Cutaneous T Cell lymphoma: Preliminary Clinical Experience With Subtotal Skin Electron Therapy.
Laughlin BS; Zaniletti I; Foster MG; Lucido J; Mangold AR; Rosenthal AC; VAN DER Walt C; Breen W; Lester S; Hoppe B; Petersen J; Armstrong MD; Bogan A; Rule WG
Anticancer Res; 2024 Apr; 44(4):1491-1497. PubMed ID: 38537978
[TBL] [Abstract] [Full Text] [Related]
2. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y
BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with
Wu W; Zhao L; Wang Y; Chen P; Yuan X; Miao L; Zhu Y; Mao J; Cai Z; Ji Y; Wang L; Jia T
Curr Probl Cancer; 2024 Feb; 48():101066. PubMed ID: 38364336
[TBL] [Abstract] [Full Text] [Related]
4. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
[TBL] [Abstract] [Full Text] [Related]
5. A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram.
Zhang X; Sun R; Zhang M; Zhao Y; Cao X; Guo R; Zhang Y; Liu X; Lyu C; Zhao M
Cancer Immunol Immunother; 2024 Jan; 73(2):33. PubMed ID: 38280081
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
7. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
[TBL] [Abstract] [Full Text] [Related]
9. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic lymphoma Group MCL7 VALERIA trial.
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Blood Adv; 2024 Jan; 8(2):407-415. PubMed ID: 38113470
[TBL] [Abstract] [Full Text] [Related]
10. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
[TBL] [Abstract] [Full Text] [Related]
11. [Novel CD19-KIRS2/Dap12-BB CAR-T treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors].
Ji SW; Hua T; Wang JJ; Shao LY; Chen ZH; Liu JY; Cheng H; Chen W; Sun C; Wang X; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1860-1865. PubMed ID: 38071073
[TBL] [Abstract] [Full Text] [Related]
12. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U
Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033
[TBL] [Abstract] [Full Text] [Related]
13. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA; Cavalcante L; Mahalingam D; Saeed A; Safran H; Ma WW; Coveler AL; Powell S; Bastos B; Davis E; Sahai V; Mikrut W; Longstreth J; Smith S; Weisskittel T; Li H; Borden BA; Harvey RD; Sahebjam S; Cervantes A; Koukol A; Mazar AP; Steeghs N; Kurzrock R; Giles FJ; Munster P
Clin Cancer Res; 2024 Feb; 30(3):522-531. PubMed ID: 37982822
[TBL] [Abstract] [Full Text] [Related]
14. Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study.
Zhang X; Qiao H; Chai X; Gao X; Ma R; Li Y; Zhu Z; Zhang M
Cancer Med; 2023 Dec; 12(24):21725-21734. PubMed ID: 37975251
[TBL] [Abstract] [Full Text] [Related]
15. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C; Gopal AK; Till BG; Shadman M; Lynch RC; Cowan AJ; Wu QV; Voutsinas J; Rasmussen HA; Blue K; Ujjani CS; Cassaday RD; Fromm JR; Fang M; Smith SD
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e33-e39.e1. PubMed ID: 37926672
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
17. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in lymphoma patients.
Zhou Y; Mu W; Wang C; Zhuo Z; Xin Y; Li H; Wang C
BMC Cancer; 2023 Oct; 23(1):1019. PubMed ID: 37872514
[TBL] [Abstract] [Full Text] [Related]
18. Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study.
Que Y; Wang J; Sun F; Wang S; Zhu J; Huang J; Zhao Z; Zhang L; Liu J; Xu J; Zhen Z; Sun X; Lu S; Zhang Y
Signal Transduct Target Ther; 2023 Oct; 8(1):392. PubMed ID: 37828033
[TBL] [Abstract] [Full Text] [Related]
19. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract] [Full Text] [Related]
20. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
[No Abstract] [Full Text] [Related]
[Next]
